Amgen (AMGN) announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA reduced the risk of death by 40% and significantly extended median overall survival by more than five months compared to standard-of-care chemotherapy in patients with small cell lung cancer who progressed on or after one line of platinum-based chemotherapy. The results will be presented at the 2025 American Society of Clinical Oncology Annual Meeting and have been published in The New England Journal of Medicine.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen’s Strong Market Position and Growth Potential Drive Buy Rating
- Amgen assumed with a Neutral at Guggenheim
- Amgen price target lowered to $328 from $329 at Piper Sandler
- Biotech Alert: Searches spiking for these stocks today
- Cautious Hold on Amgen: Navigating Competitive Challenges and Market Potential for MariTide